Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Involvement of insulin-like growth factor-I in the control of glucose homeostasis.

Clemmons DR.

Curr Opin Pharmacol. 2006 Dec;6(6):620-5. Epub 2006 Oct 9. Review.

PMID:
17030015
2.

Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus.

Mohamed-Ali V, Pinkney J.

Treat Endocrinol. 2002;1(6):399-410. Review.

PMID:
15832492
3.

Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?

Dunger DB, Acerini CL.

Diabet Med. 1997 Sep;14(9):723-31. Review.

PMID:
9300221
4.

The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis.

Holt RI, Simpson HL, Sönksen PH.

Diabet Med. 2003 Jan;20(1):3-15. Review.

PMID:
12519314
5.

Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.

Resmini E, Minuto F, Colao A, Ferone D.

Acta Diabetol. 2009 Jun;46(2):85-95. doi: 10.1007/s00592-009-0112-9. Epub 2009 Mar 26. Review.

PMID:
19322513
6.
7.

Clinical uses of insulin-like growth factor I.

Bondy CA, Underwood LE, Clemmons DR, Guler HP, Bach MA, Skarulis M.

Ann Intern Med. 1994 Apr 1;120(7):593-601. Review.

PMID:
8116999
8.
9.

Metabolic impact of puberty on the course of type 1 diabetes.

Acerini CL, Williams RM, Dunger DB.

Diabetes Metab. 2001 Sep;27(4 Pt 2):S19-25. Review. Erratum in: Diabetes Metab 2001 Nov;27(5 Pt 1):624. Acerini, L [corrected to Acerini, CL]; Williams, M [corrected to Williams, RM]; Dunger, B [corrected to Dunger, DB].

PMID:
11787432
10.

Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance.

Froesch ER, Bianda T, Hussain MA.

Diabetes Metab. 1996 Jul;22(4):261-7. Review.

PMID:
8767173
11.

Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.

Ranke MB.

Trends Endocrinol Metab. 2005 May-Jun;16(4):190-7. Review.

PMID:
15860416
12.

Impact of treatment with recombinant human GH and IGF-I on visceral adipose tissue and glucose homeostasis in adults.

Yuen KC, Dunger DB.

Growth Horm IGF Res. 2006 Jul;16 Suppl A:S55-61. Epub 2006 Apr 18. Review.

PMID:
16624605
13.

Characteristics of the somatotropic axis in insulin dependent diabetes mellitus.

Mercado M, Baumann G.

Arch Med Res. 1995 Summer;26(2):101-9. Review.

PMID:
7620273
14.

Insulin-like growth factor-I and diabetes. A review.

Simpson HL, Umpleby AM, Russell-Jones DL.

Growth Horm IGF Res. 1998 Apr;8(2):83-95. Review.

PMID:
10987675
15.

Metabolic actions of insulin-like growth factor-I in normal physiology and diabetes.

Clemmons DR.

Endocrinol Metab Clin North Am. 2012 Jun;41(2):425-43, vii-viii. doi: 10.1016/j.ecl.2012.04.017. Review.

16.

Insulin-like growth factor-1 therapy in diabetes: physiologic basis, clinical benefits, and risks.

Kolaczynski JW, Caro JF.

Ann Intern Med. 1994 Jan 1;120(1):47-55. Review.

PMID:
8250456
17.

Inactivation of muscle insulin and IGF-I receptors and insulin responsiveness.

Le Roith D, Kim H, Fernandez AM, Accili D.

Curr Opin Clin Nutr Metab Care. 2002 Jul;5(4):371-5. Review.

PMID:
12107371
18.
19.

Studies involving the GH-IGF axis: Lessons from IGF-I and IGF-I receptor gene targeting mouse models.

Yakar S, Pennisi P, Kim CH, Zhao H, Toyoshima Y, Gavrilova O, LeRoith D.

J Endocrinol Invest. 2005;28(5 Suppl):19-22. Review.

PMID:
16114270
20.

Molecular mechanisms of skeletal muscle insulin resistance in type 2 diabetes.

Bouzakri K, Koistinen HA, Zierath JR.

Curr Diabetes Rev. 2005 May;1(2):167-74. Review.

PMID:
18220592

Supplemental Content

Support Center